Windlas Biotech Limited IPO: Issue Price, Listing Gain and Share Price Now
Windlas Biotech Limited listed on 16-Aug-2021 at ₹406.7 against an issue price of ₹460 , a listing change of -11.59%. It last traded at ₹985.3. This page is the record of that issue and what has happened to it since — reported figures only.
Windlas Biotech Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹460 |
| Listing price (listing-day close) | ₹406.7 |
| Listing gain | -11.59% |
| Price now | ₹985.3 |
| Change from issue price | +114.20% |
| Change from listing-day close | +142.27% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Windlas Biotech Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹460 |
| Issue size | ₹401.54 Cr |
| Fresh issue | ₹165 Cr |
| Offer for sale | ₹236.54 Cr |
| Issue opened | 04-Aug-2021 |
| Issue closed | 06-Aug-2021 |
| Listed on | 16-Aug-2021 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | Dam Capital (left lead) |
How the Windlas Biotech Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 24.40x |
| NII | 15.73x |
| Retail | 24.22x |
| Total | 22.44x |
Windlas Biotech Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹2,038 Cr |
| Trailing P/E | 30.70x |
| Return on capital employed | 15.9% |
| Return on equity | 12.2% |
| 52-week high | ₹1,045 |
| 52-week low | ₹697 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Windlas Biotech Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.